Save time and get answers to complex questions with AI chat
What is dabrafenib mesylate msn patent issue?Can wine consumption affect lipitor's cholesterol lowering ability?Can i take anti histamine with statin?Drugpatentwatch crizotinib?Sun pharma bortezomib?
See the DrugPatentWatch profile for vascepa
Early Benefits of Vascepa: Short-term Effects Vascepa, a prescription fish-oil medication, is primarily used to treat high triglycerides in adults [1]. It contains a highly concentrated form of omega-3 fatty acid, eicosapentaenoic acid (EPA). Studies have shown that EPA, a key component of Vascepa, can reduce triglyceride levels and provide cardiovascular benefits in as little as 12 weeks [2]. Long-term Effects of Vascepa Therapy Clinical trials have demonstrated that long-term treatment with Vascepa can lead to sustained reductions in triglyceride levels, as well as a lower risk of cardiovascular events such as heart attacks and strokes [3]. A landmark trial published in 2019 showed that Vascepa reduced the risk of major adverse cardiovascular events by 25% over a 5-year period compared to a placebo [4]. When to Expect Results While individual results may vary, patients can typically expect to see the benefits of Vascepa within the first few weeks to months of treatment. Here's a general timeline for what patients can expect: * 1-4 weeks: Reduction in triglyceride levels, as well as some initial cardiovascular benefits * 12 weeks: Established reduction in triglyceride levels, as well as noticeable improvements in cardiovascular health * 5 years: Sustained reduction in triglyceride levels, as well as reduced risk of cardiovascular events Please consult with your healthcare provider for a personalized treatment plan and to discuss your individual results and expectations. Sources: [1] https://www.drugpatentwatch.com/drug/vascepa-ethyl-eicosapentaenoic-ethyl-ester/ [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341417/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541410/ [4] https://www.nejm.org/doi/full/10.1056/NEJMoa1801314
Other Questions About Vascepa :